<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04490057</url>
  </required_header>
  <id_info>
    <org_study_id>2000026332</org_study_id>
    <secondary_id>R01CA243910</secondary_id>
    <nct_id>NCT04490057</nct_id>
  </id_info>
  <brief_title>A Smart Approach to Treating Tobacco Use Disorder in Persons Living With HIV</brief_title>
  <acronym>SMARTTT</acronym>
  <official_title>A Smart Approach to Treating Tobacco Use Disorder in Persons Living With HIV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Many people living with HIV (PLWH) smoke. Smoking in these individuals is often undertreated.
      This study plans to assess the ability of various clinical pathways involving tobacco
      treatment medications and contingency management (paying smokers for not smoking) to improve
      smoking cessation in a group of PLWH.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Using a Sequential Multiple Assignment Randomized Trial (SMART) design, this project is a
      two-arm, two-stage randomized trial of 632 adult PWH who smoke cigarettes and receive care in
      one of three health systems. At inception, participants will be randomized to either
      combination nicotine replacement therapy (NRT, patch + short-acting NRT) or combination
      NRT+contingency management (CM). At 12 weeks, responders (non-smoking participants confirmed
      by exhaled carbon monoxide [eCO]) in both arms will receive 12 more weeks of the same
      treatment. Non-responders (participants with continued smoking by self-report and/or eCO) in
      both the NRT and NRT+CM arms will be re-randomized to 12 weeks of treatment, either with
      medication switch to varenicline (VAR) or intensified level of CM (start CM if no CM during
      first 12 weeks, or CM with higher reward schedule [&quot;CM plus&quot;] if NRT+CM group initially). The
      intervention will be delivered by trained clinical pharmacists. The primary outcome will be
      eCO-confirmed abstinence at 24 weeks post-enrollment. The specific aims of the proposed study
      are to: (1) identify the optimal adaptive approach to promote eCO-confirmed smoking
      abstinence (2) study the effectiveness of various adaptive strategies on CD4 count, HIV viral
      suppression, and VACS index (validated measure of morbidity and mortality risk); and (3)
      grounded in implementation science and using a Hybrid Effectiveness-Implementation Type I
      design, identify barriers and facilitators to delivering our intervention to inform future
      implementation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">September 2024</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Sequential multiple assignment randomized trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>eCO confirmed abstinence at 24 weeks</measure>
    <time_frame>24 weeks from baseline</time_frame>
    <description>Abstinence from tobacco confirmed by exhaled carbon monoxide</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>VACS index 2.0</measure>
    <time_frame>24 weeks from baseline</time_frame>
    <description>A validated measure of morbidity and mortalityviral load,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4 Count</measure>
    <time_frame>24 weeks from baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV Viral Load</measure>
    <time_frame>24 weeks from baseline</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Identification of Barriers and Facilitators</measure>
    <time_frame>Baseline and Up to 4 years</time_frame>
    <description>Using a Hybrid Effectiveness-Implementation Type I design, identify barriers and facilitators to delivering our intervention to inform future implementation.</description>
  </other_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">632</enrollment>
  <condition>Tobacco Use Cessation</condition>
  <arm_group>
    <arm_group_label>12 wks NRT+CM / 12 wks NRT+CM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nicotine replacement therapy combined with contingency management. Responders remain on same treatment for second 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>12 wks NRT+CM/ 12 wks VAR+CM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nicotine replacement therapy combined with contingency management. Non-responders switch to varenicline combined with contingency management for second 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>12 wks NRT+CM/12 wks NRT+CM plus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nicotine replacement therapy combined with contingency management Non-responders switch to nicotine replacement therapy combined with intensified contingency management for second 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>12 wks NRT/ 12 wks NRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nicotine replacement therapy alone. Responders remain on nicotine replacement therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>12 wks NRT/ 12 wks VAR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nicotine replacement therapy alone. Non-responders switch to varenicline alone for second 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>12 wks NRT/ 12 wks NRT+CM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nicotine replacement therapy alone. Non-responders switch to nicotine replacement therapy combined with contingency management for second 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine patch, nicotine gum, nicotine nasal spray, nicotine inhaler</intervention_name>
    <description>Participants will be prescribed both long-acting and short-acting nicotine replacement therapy.</description>
    <arm_group_label>12 wks NRT+CM / 12 wks NRT+CM</arm_group_label>
    <arm_group_label>12 wks NRT+CM/ 12 wks VAR+CM</arm_group_label>
    <arm_group_label>12 wks NRT+CM/12 wks NRT+CM plus</arm_group_label>
    <arm_group_label>12 wks NRT/ 12 wks NRT</arm_group_label>
    <arm_group_label>12 wks NRT/ 12 wks NRT+CM</arm_group_label>
    <arm_group_label>12 wks NRT/ 12 wks VAR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Varenicline</intervention_name>
    <description>Participants will be prescribed varenicline (Chantix).</description>
    <arm_group_label>12 wks NRT+CM/ 12 wks VAR+CM</arm_group_label>
    <arm_group_label>12 wks NRT/ 12 wks VAR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Contingency Management</intervention_name>
    <description>Particpants will be financially rewarded for abstinence to tobacco.</description>
    <arm_group_label>12 wks NRT+CM / 12 wks NRT+CM</arm_group_label>
    <arm_group_label>12 wks NRT+CM/ 12 wks VAR+CM</arm_group_label>
    <arm_group_label>12 wks NRT+CM/12 wks NRT+CM plus</arm_group_label>
    <arm_group_label>12 wks NRT/ 12 wks NRT+CM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV positive;

          -  Receiving HIV care at Yale-New Haven Hospital, Mount Sinai Hospital, or SUNY Downstate
             STAR clinic;

          -  Have smoked &gt;100 cigarettes in lifetime;

          -  Currently smokes some days or every day;

          -  Smokes, on average, &gt; 5 cigarettes per day;

          -  Able to provide written informed consent.

        Exclusion Criteria:

          -  Using only non-cigarette nicotine products (i.e., e-cigs, Juul, etc.);

          -  Currently using NRT, VAR (defined as use in the prior 7 days);

          -  Self-report or urine testing confirming pregnancy, nursing, or trying to conceive;

          -  Life-threatening or unstable medical, surgical, or psychiatric condition;

          -  Inability to provide at least one collateral contact (family member or friend);

          -  Living out of state;

          -  Unable to read or understand English.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>E. Jennifer Edelman, MD, MHS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steven Bernstein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elizabeth Porter, MBA</last_name>
    <phone>203-737-3347</phone>
    <email>elizabeth.porter@yale.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>E. Jennifer Edelman, MD, MHS</last_name>
      <phone>203-737-7115</phone>
      <email>ejennifer.edelman@yale.edu</email>
    </contact>
    <contact_backup>
      <last_name>Elizabeth Porter, MBA</last_name>
      <phone>203-737-3347</phone>
      <email>elizabeth.porter@yale.edu</email>
    </contact_backup>
    <investigator>
      <last_name>E. Jennifer Edelman, MD, MHS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SUNY Downstate STAR Clinic</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jessica Yager, MD</last_name>
      <email>jessica.yager@downstate.edu</email>
    </contact>
    <contact_backup>
      <last_name>Mayange Frederick</last_name>
      <phone>718-270-8641</phone>
      <email>mayange.frederick@downstate.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jessica Yager, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keith Sigel, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Emily Federmann</last_name>
      <phone>212-824-7455</phone>
      <email>emily.federmann@mountsinai.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 22, 2020</study_first_submitted>
  <study_first_submitted_qc>July 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2020</study_first_posted>
  <last_update_submitted>July 25, 2020</last_update_submitted>
  <last_update_submitted_qc>July 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
    <mesh_term>Varenicline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

